BMY Sentiment Analysis

Insider Monkey Presents a Bull Case Theory for Bristol-Myers Squibb Company

Published on January 26, 2025

According to a recent report by Insider Monkey, Bristol-Myers Squibb Company (NYSE: BMY) is attracting a lot of attention from institutional investors who currently own 77% of the company. The pharmaceutical giant has been making waves in the industr...

Is Bristol-Myers Squibb Company the New Game-Changer in the Pharmaceutical Industry?

Published on January 25, 2025

Renowned investor Jim Cramer has recently touted Bristol-Myers Squibb Company (BMY) as the one that everyone in the industry is talking about. With a history of groundbreaking treatments and a solid reputation, Bristol-Myers Squibb has become a buzzw...

Bristol-Myers Squibb Utilizes Cobenfy for Alzheimer's Treatment

Published on January 24, 2025

Bristol-Myers Squibb Company (BMY) has recently placed its faith in the potential of Cobenfy, a breakthrough therapy for Alzheimer's treatment. Despite the overall gains in the market, BMY stock experienced a slight dip. Cobenfy is a promising soluti...

Bristol Myers Squibb Stock Shows Resilience in a Volatile Market

Published on January 22, 2025

Amidst a volatile stock market, Bristol Myers Squibb (BMY) has managed to maintain its stability and even show some gains....

Bristol Myers Squibb Rises on Dow Jones Sustainability Index

Published on January 15, 2025

Bristol Myers Squibb Company (BMY) has been recognized for its commitment to sustainability, being named to the Dow Jones Sustainability Index North America for the second consecutive year. This prestigious index acknowledges companies that demonstra...

Exciting News: Bristol Myers Squibb Named to Dow Jones Sustainability Index North America for Second Consecutive Year

Published on January 14, 2025

Bristol Myers Squibb, a leading pharmaceutical company, has been recognized for its commitment to sustainability and named to the prestigious Dow Jones Sustainability Index North America for the second year in a row. This index recognizes companies t...

New Drug Approval Boosts BMY Stocks: Analysts Recommend Buying Bristol-Myers Squibb Shares

Published on January 13, 2025

Bristol-Myers Squibb Company (NYSE: BMY) experienced a significant rise in its stock value after the approval of a groundbreaking drug. The new medication, which has been developed to treat a rare form of cancer, has shown promising results in clinic...

Bristol Myers Squibb Company: A Leader in the Pharmaceutical Industry

Published on January 10, 2025

Bristol Myers Squibb Company (BMY) is a renowned pharmaceutical company that continues to make waves in the industry....

Bristol-Myers Squibb Announces Breakthrough in Cancer Treatment Research

Published on January 9, 2025

Bristol-Myers Squibb, a leading pharmaceutical company, has made a major breakthrough in cancer treatment research....

Bristol-Myers Squibb: Boost in Returns and Upcoming Healthcare Conference Presentation

Published on January 8, 2025

Bristol-Myers Squibb (NYSE:BMY) investors have reason to celebrate with a solid return of 2....

Is Bristol-Myers Squibb Company BMY Among the Best Pharma Dividend Stocks to Buy In 2024?

Published on January 7, 2025

Bristol-Myers Squibb Company (BMY) is gaining attention as one of the best pharmaceutical dividend stocks to buy in 2024....

Is Trending Stock Bristol Myers Squibb Company BMY a Buy Now?

Published on January 6, 2025

Bristol Myers Squibb Company (BMY) continues to attract attention in the stock market due to its positive performance and the potential for future growth. The pharmaceutical giant is set to present at J.P. Morgan's 43rd Annual Healthcare Conference, ...

Bristol-Myers Squibb Company to Expand its Healthcare Offerings at J.P. Morgan Conference

Published on January 4, 2025

Bristol-Myers Squibb Company (BMY) is set to present at J.P....

Is Bristol-Myers Squibb Co. (BMY) the Best Stock for 10 Years?

Published on January 2, 2025

Bristol-Myers Squibb Company (BMY) has garnered significant attention in recent times, prompting investors to ponder if it could be the best stock for the next decade. With its strong track record and promising pipeline, BMY has become an attractive ...

Is Bristol-Myers Squibb Co. the Game-Changer in the Pharma Industry?

Published on January 1, 2025

Bristol-Myers Squibb Company (BMY), a renowned pharmaceutical giant, has been making significant strides in the industry....

Is Bristol-Myers Squibb Co. BMY the Best Stock for 10 Years?

Published on January 1, 2025

Bristol-Myers Squibb Company (BMY) has been grabbing headlines lately as investors wonder whether it is the best stock to hold for the long term. With a strong track record and a focus on innovation, BMY has positioned itself as a leader in the pharm...

Bristol-Myers Squibb Strengthens Investor Confidence with Increased Dividend Payout

Published on December 31, 2024

Bristol-Myers Squibb, a renowned pharmaceutical company listed on the NYSE as BMY, has announced a significant increase in its dividend payout compared to the previous year. The company, known for its innovative breakthroughs in the healthcare indust...

Bristol Myers Squibb Receives FDA Approval for Cancer Treatment

Published on December 30, 2024

The Bristol Myers Squibb Company has recently received FDA approval for a groundbreaking cancer treatment....

Bristol Myers Squibb: Promising Results from Phase 3 Psoriatic Arthritis Trials

Published on December 29, 2024

Bristol Myers Squibb (BMY) recently announced positive topline results from its Phase 3 trials evaluating Sotyktu deucravacitinib in adults with psoriatic arthritis. The trials showed promising results, meeting key endpoints and demonstrating the pot...

Bristol-Myers Squibb Makes Significant Progress in Psoriatic Arthritis Treatment

Published on December 29, 2024

Bristol-Myers Squibb Company, a leading pharmaceutical company, has announced promising results from two Phase 3 trials evaluating the effectiveness of its new drug, Sotyktu deucravacitinib, in treating psoriatic arthritis in adults. The trials have ...

Positive Results from Psoriatic Arthritis Trials Boost Bristol-Myers Squibb Stock

Published on December 26, 2024

Bristol-Myers Squibb Company (BMY), a leading pharmaceutical company, has recently announced positive topline results from two pivotal Phase 3 trials evaluating its drug Sotyktu deucravacitinib in adults with psoriatic arthritis. The trials have show...

Jim Cramer on Bristol-Myers Squibb Company BMY: This Stock Has Been Hot Since The Summer

Published on December 26, 2024

According to financial analyst Jim Cramer, Bristol-Myers Squibb Company (BMY) has been performing exceptionally well in the stock market since the summer season. The company's shares have experienced a significant surge in value, making it an attract...

insitro Receives 25 Million in Milestone Payments from Bristol Myers Squibb for ALS Research

Published on December 25, 2024

Bristol Myers Squibb Company (BMY) has announced that it will provide insitro with 25 million dollars in milestone payments....

Is Bristol-Myers Squibb Company BMY the Best Weight Loss Stock to Buy Now According to Hedge Funds?

Published on December 24, 2024

Bristol-Myers Squibb Company (BMY) is gaining attention from investors as it emerges as a potential weight loss stock to buy....

Bristol-Myers Squibb Company BMY Announces Exciting Developments in Cancer Research

Published on December 24, 2024

Bristol-Myers Squibb Company BMY, a leading pharmaceutical company, has recently made significant advancements in cancer research that are capturing the attention of investors and medical professionals alike. The company announced that their groundbr...